Sign in

CIK 0001829802

  • Emerging growth company

Faeth Therapeutics, Inc.

Sign in to watch
Ticker
FTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 512-200-2982
Business address
701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
Former names
Sensei Biotherapeutics, Inc.
  1. 4 Open-market buy 10% owner bought 8,000 shares at $13.75 ($110,000)
  2. 4 Open-market buy Director bought 8,000 shares at $13.75 ($110,000)
  3. 4 Open-market buy 10% owner bought 5,000 shares at an average $15.16 ($75,800)
  4. 4 Open-market buy Director bought 5,000 shares at an average $15.16 ($75,800)
  5. 4 Open-market buy Director bought 3,000 shares at $16.25 ($48,750)
  6. 4 Open-market buy 10% owner bought 3,000 shares at $16.25 ($48,750)
  7. 4 Open-market buy Director bought 5,000 shares at $16.25 ($81,250)
  8. 4 Open-market buy 10% owner bought 5,000 shares at $16.25 ($81,250)
  9. 4 Open-market buy Director bought 31,000 shares at an average $16.48 ($510,862)
  10. 4 Open-market buy 10% owner bought 31,000 shares at an average $16.48 ($510,862)
  11. 4 Open-market buy Director bought 20,300 shares at an average $17.79 ($361,070)
  12. 4 Open-market buy 10% owner bought 20,300 shares at an average $17.79 ($361,070)
  13. 4 Open-market buy 10% owner bought 9,802 shares at $18.88 ($185,062)
  14. 4 Open-market buy Director bought 9,802 shares at $18.88 ($185,062)
  15. 4 Open-market buy Director bought 11,786 shares at $19.77 ($233,009)
  16. 4 Open-market buy 10% owner bought 11,786 shares at $19.77 ($233,009)
  17. 4 Open-market buy Director bought 753 shares at $19.75 ($14,872)
  18. 4 Open-market buy 10% owner bought 753 shares at $19.75 ($14,872)
  19. 4 Conversion Director acquired 301,769 shares (conversion)
  20. 4 Conversion Director acquired 2,407,328 shares (conversion)

Page 11 of 13 · 245 filings